

New Brand Drug Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Oliceridine (Olinvyk™) Injection	Opioid Agonist	Pain	Launch anticipated following DEA assigning controlled substance schedule. Approved August 7, 2020.
Metoclopramide Nasal Spray (Gimoti™)	Gastrointestinal Agent	Gastroparesis	Launch anticipated Q4 2020. Approved June 19, 2020.
Celecoxib Oral Liquid (Elyxyb™)	NSAID	Migraine Headache Treatment	Launch pending. Approved May 5, 2020.
Benzhydrocodone HCl/Acetaminophen (Apadaz™)	Opioid Analgesic – Immediate Release	Pain	Launch pending. Approved February 23, 2018.
Buprenorphine Depot Injection (Brixadi™)	Opioid Agonist	Treatment of Opioid Addiction	Anticipated approval December 1, 2020 following expiration of exclusivity period for Sublocade™.
Zolmitriptan (Qtrypta™) Patch	Migraine Agent	Migraine Headache Treatment	FDA review anticipated October 2020.
Celecoxib/Tramadol	NSAID/Opioid Agonist	Pain	FDA review pending.
Ansofaxine	Antidepressant	Major Depressive Disorder	FDA review anticipated December 2020.
Oxycodone HCl (Aximris XR™)	Opioid Analgesic – Extended Release	Pain	FDA advisory committee recommended against approval.
Naloxone Injection (Zimhi™)	Opioid Antagonist	Opioid Overdose	FDA review anticipated November 2020.
Oxycodone HCl/Naltrexone HCl (SequestOx™)	Opioid Analgesic – Immediate Release	Pain	FDA review pending after declining to approve in 2016.

Generic Pipeline

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Apixaban (Eliquis®)	Anticoagulant	Treatment/ Prophylaxis of Deep Vein Thrombosis	Generics approved December 23, 2019, but settlements expected to delay launch for at least a few years.
Naloxone HCl (Narcan®) Nasal Spray	Opioid Antidote	Opioid Overdose	Launch pending. Generic approved April 19, 2019.
Emtricitabine/Tenofovir (Truvada®)	Antiretroviral	HIV Post-Exposure Prophylaxis	Generic anticipated late 2020.

Report

Monthly New Drug and First Time Generic

August 2020



Available in the Last 12 Months

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Rimegepant (Nurtec™ ODT)	CGRP Antagonist	Migraine Headache Treatment	March 2020
Ubrogepant (Ubrelvy™)	CGRP Antagonist	Migraine Headache Treatment	March 2020
Lasmiditan (Reyvow™)	Migraine Agent	Migraine Headache Treatment	January 2020
Sumatriptan Nasal Spray (Tosymra™)	Migraine Agent	Migraine Headache Treatment	October 2019

Newly Available Generics

Albuterol Sulfate (Proventil® HFA)	Inhaled Bronchodilator	Asthma	April 2020
Naproxen/Esomeprazole (Vimovo®)	NSAID/GI Protectant	Pain/Stomach Ulcer Prophylaxis	February 2020
Albuterol Sulfate (ProAir® HFA)	Inhaled Bronchodilator	Asthma	February 2020
Hydrocodone Bitartrate (Zohydro® ER)	Opioid Analgesic – Extended Release	Pain	January 2020
Doxepin (Silenor®)	Tricyclic Antidepressant	Sleep Disorders	January 2020

Discontinuations

Medication (Brand Name)	Drug Class	Therapeutic Use	Status Update
Ranitidine (Zantac®)	H-2 Receptor Antagonist	Heartburn/Stomach Ulcer Prophylaxis	FDA asked all manufacturers to remove product from the market on April 1, 2020.
Morphine Sulfate/Naltrexone HCl (Embeda®)	Opioid Analgesic – Extended Release Abuse Deterrent	Pain	Stop sale date November 15, 2019 with anticipated unavailability early 2020.